Clinical trials: Oncologic
Acute Lymphobkastic Leukemia, Medication Adherence
The AYA Oncology Self-care Movement
This trial will test the impact of a social media intervention for improving oral chemotherapy adherence among adolescents and young adults (AYAs) with acute lymphoblastic leukemia.
- Trial name
- #AYAOSM (NCT07724652)
- Testing
- Educational Website, #AYAOSM
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Reconstruction of Massive Bone Loss (Oncologic and Non-oncologic)
Prospective Evaluation of Adler Laboratory's Massive Prosthetic Implants in Oncological and Non-oncological Situations
Massive prostheses are the standard treatment for extensive bone loss, whether caused by cancer or other factors (complex fractures, multiple revisions, infections).
- Trial name
- IMPULSION (NCT07369778)
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Nantes University Hospital
Lung Cancer
Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology
Lung cancer kills 160,000 patients annually; this represents 28% of all US cancer deaths. The overall year survival rate has only improved from 12% to 17% in 33 years.
- Trial name
- NCT02123797
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Baptist Memorial Health Care Corporation
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Febrile Neutropenia, Neutropenia
Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients
Febrile neutropenia (FN) is a major life-threatening treatment complication in cancer patients undergoing intensive chemotherapy. Endogenous flora is considered to be one of the main sources of infections during neutropenia.
- Conditions
- Febrile Neutropenia, Neutropenia, Infection in an Immunocompromised Host, Cancer
- Trial name
- FENSY (NCT02544685)
- Testing
- Probio-Fix Inum, Beneo Synergy 1
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- S&D Pharma SK s.r.o.
Cancer, NGS
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
- Conditions
- Cancer, NGS, Tumor, RARE DISEASE
- Trial name
- SONCO (NCT07147465)
- Where
- 3 sites in France
- Volunteers
- 3,149 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Pediatric Tumor, Familial Cancer
Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia
Background. Cancer is the leading cause of death by disease in children. Most pediatric tumors differ from adult tumors in terms of biological and clinical characteristics.
- Conditions
- Pediatric Tumor, Familial Cancer, Solid Tumor, Childhood, Hematological Tumor
- Trial name
- ALADIN (NCT04471961)
- Testing
- Exome sequencing in pediatrics cancers
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Leukemia
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and combining drugs in different ways may kill more cancer cells.
- Trial name
- NCT00003783
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- 58 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- Children's Oncology Group
Participants Undergoing Anthracycline Chemotherapy
Remote Ischemic Conditioning in Oncology
This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements…
- Trial name
- RICO (NCT04805346)
- Testing
- autoRIC®
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic…
- Trial name
- NCT03932903
- Testing
- ADAPTS (ADherence Assessments and Personalized Timely Support).
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Localized Cancer
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment.
- Trial name
- NEOREM (NCT07262489)
- Testing
- Each therapeutic NEOREM sub-protocol will mention the description of intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- UNICANCER
Infection
Community Central Line Infection Prevention Trial
The overall goal of this Community Central Line Infection Prevention (CCLIP) trial, supported by grant R01 HS022870 from the Agency for Healthcare Research and Quality, is to determine whether use of a promising new intervention…
- Trial name
- CCLIP (NCT02351258)
- Testing
- 70% Isopropyl alcohol embedded caps, Usual Care
- Where
- 16 sites in United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Pregnancy Related, Immune-mediated Diseases
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
What is this project about? This project aims to better understand how the immune system develops in babies whose mothers received immunomodulatory treatments during pregnancy.
- Trial name
- NEWbornIMMPACT (NCT07033663)
- Testing
- Monoclonal antibody
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundació Sant Joan de Déu
Medulloblastoma, Recurrent Medulloblastoma
Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma
Children with medulloblastoma, an aggressive brain tumor, require prolonged and complex multimodal therapy. Their primary parental caregivers bear the main responsibility for ensuring treatment adherence, yet the psychological…
- Trial name
- NCT07660458
- Testing
- Not applicable- observational study
- Where
- China
- Sponsor
- West China Hospital
Pediatric Radiation
Planning Margin Requirements for Pediatric Radiation Oncology
The planning target volume (PTV) and planning organ at risk volume (PRV) margins used for pediatric radiation therapy are empiric, and quantitative assessment of these margins is needed to improve therapy planning and delivery.
- Trial name
- NCT00704613
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- St. Jude Children's Research Hospital
Congenital Anomaly, Pediatric Cancer
Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
One of the strongest risk factors for cancer in children and adolescents is being born with a congenital anomaly. In fact, data from registry linkage studies imply that 10-15% of childhood cancer risk could be attributable to…
- Trial name
- NCT05071859
- Testing
- Whole Genome Sequencing, Questionnaire Administration, Biospecimen collection
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
This is a compassionate use protocol to allow patients with advanced neuroblastoma palliative access to 131I-metaiodobenzylguanidine (131I-MIBG).
- Trial name
- NCT01370330
- Testing
- Metaiodobenzylguanidine (MIBG)
- Where
- United States
- Sponsor
- Kieuhoa Vo
Diffuse Large Cell Lymphoma, Burkitt's Lymphoma
Treatment for Advanced B-Cell Lymphoma
To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and…
- Conditions
- Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
- Trial name
- REBOOT (NCT01859819)
- Testing
- Rituximab, IT Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- New York Medical College
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
- Trial name
- NCT01596400
- Testing
- granisetron transdermal system, Granisetron IV
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd